Honeywell's Quantinuum has established a $12.7 billion target for its IPO following initial expectations of $20 billion.

      Quantinuum, a quantum-computing firm predominantly owned by Honeywell, is aiming for a valuation of $12.7 billion in its upcoming US IPO, as reported by Reuters on Tuesday. This figure is significantly lower than the $20 billion-plus valuation that emerged earlier in May during the company's S-1 filing.

      The updated valuation represents an approximate 27% increase from the $10 billion pre-money valuation established in Honeywell's $600 million equity raise last September. It is also around 36% lower than the previous IPO whispers, indicating that bankers may have adopted a more cautious view of market demand for pre-revenue quantum companies or that the firm has opted for a more conservative pricing strategy to ensure a solid debut.

      In 2025, Quantinuum reported revenues of $31 million, while the S-1 suggested that its operating losses are significantly larger. If successful, this IPO would mark the largest quantum-computing listing to date and the first instance of a private quantum company transitioning directly from advanced hardware development to a public valuation exceeding $10 billion.

      Peer companies in the public market, such as IonQ, Rigetti, and D-Wave, are trading at valuations below that threshold, despite similar or smaller revenue figures. Quantinuum's higher valuation is attributed to its hardware strategy involving trapped-ion qubits, which are generally viewed as having a superior error-correction capability compared to the superconducting approach utilized by many publicly listed quantum firms.

      Honeywell’s majority shareholding makes this IPO a dual-purpose venture for portfolio management. The industrial conglomerate has spent the last two years preparing its investors for the eventual divestiture of its quantum business; this listing will create a publicly tradable asset and provide Honeywell shareholders with clear exposure to the quantum sector rather than an indirect stake. The company has not revealed how much of its ownership it plans to retain post-offering.

      The revised target of $12.7 billion occurs within a notably active quantum funding landscape. Earlier this month, Nord Quantique achieved a $1.4 billion valuation in a Fidelity-backed funding round; Finland’s IQM has been persistently raising capital; and the European quantum venture fund 55 North recently closed its first €134 million in October.

      None of these entities have yet reached the scale that Quantinuum is pursuing, which is why the IPO will serve in part as a gauge for what public markets are prepared to pay for the sector.

      The drop from $20 billion to $12.7 billion is a significant point of discussion. Companies with pre-revenue or nominal revenue in the field of frontier physics have recently found, as evidenced by CoreWeave and other AI-related IPOs, that public investors are more cautious compared to the assumptions of late-stage private rounds.

      A target of $12.7 billion, while high when considering Quantinuum’s 2025 revenue, reflects a disciplined approach in relation to private market valuations; it suggests the underwriters have adjusted expectations based on the demand seen in their order book. Reuters did not disclose the names of the leading bookrunners for the IPO.

      The roadshow is anticipated to commence within weeks, and Quantinuum plans to list under the ticker QNT on Nasdaq once the offering is priced.